Form 8-K IRONWOOD PHARMACEUTICALS For: Feb 18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BTIG Sees Opportunity in Ironwood Pharma (IRWD) Weakness; Affirms at 'Buy'
February 19, 2016 7:50 AM ESTBTIG affirms its Buy rating and $15 price target on Ironwood Pharmaceuticals (Nasdaq: IRWD) following IRWD's Q4 results issued Thursday night.
Analyst Timothy Chiang noted that IRWD's Q4 included $53.3 million of collaboration revenue (vs. our $44 million estimate) and a loss per share of... More
